About theralink technologies - THER
Theralink Technologies, Inc. is a precision medicine company, which engages in the development of novel cancer immunotherapy products. It offers the reverse phase protein array technology platform that can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. The company was founded on March 18, 2005 and is headquartered in Golden, CO.
THER At a Glance
Theralink Technologies, Inc.
15000 West 6th Avenue
Golden, Colorado 80401
| Phone | 1-720-420-0074 | Revenue | 606.80K | |
| Industry | Biotechnology | Net Income | -30,907,505.00 | |
| Sector | Health Technology | 2023 Sales Growth | 6.848% | |
| Fiscal Year-end | 09 / 2024 | Employees | 16 | |
| View SEC Filings |
THER Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.124 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.848 |
| Enterprise Value to Sales | 40.046 |
| Total Debt to Enterprise Value | 0.813 |
THER Efficiency
| Revenue/Employee | 37,924.75 |
| Income Per Employee | -1,931,719.063 |
| Receivables Turnover | 25.378 |
| Total Asset Turnover | 0.223 |
THER Liquidity
| Current Ratio | 0.032 |
| Quick Ratio | 0.032 |
| Cash Ratio | 0.025 |
THER Profitability
| Gross Margin | -849.492 |
| Operating Margin | -1,440.468 |
| Pretax Margin | -5,093.558 |
| Net Margin | -5,093.558 |
| Return on Assets | -1,134.49 |
| Return on Equity | N/A |
| Return on Total Capital | 168.397 |
| Return on Invested Capital | N/A |
THER Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -107.67 |
| Total Debt to Total Assets | 693.441 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -6.159 |